Source credit: UCLA Health.
UCLA researchers report that creatine, best known to lifters as a performance and muscle-support supplement, helped energize dendritic immune cells in mouse models and human cell experiments. The work points to a possible way to support anti-tumor immune activity, but it is still early research and has not shown that taking creatine treats cancer in people.
Short Summary
The UCLA team found that dendritic cells inside tumors appeared to rely on creatine transport for survival, activation, and communication with T cells. In mouse melanoma models, creatine supplementation slowed tumor growth and increased activation markers in tumor-infiltrating dendritic cells. Lab tests with human dendritic cells also suggested stronger activation, which the researchers say could eventually matter for dendritic-cell vaccine development.
Why it matters for lifters
Creatine already has a strong sports-nutrition evidence base for strength and high-intensity performance when used appropriately. This study is interesting because it looks outside the usual gym outcomes and asks how creatine metabolism may affect immune-cell energy. For lifters, the practical takeaway is restraint: do not treat a preclinical cancer-immunology finding as a reason to mega-dose, replace medical care, or believe broad wellness claims that go beyond the data.
What to watch next
The next useful signal would be controlled human research showing whether creatine changes immune markers or treatment outcomes in specific clinical settings. Until then, athletes should evaluate creatine for established training goals, product quality, kidney-health considerations, medication interactions, and individual medical history rather than cancer-treatment promises.
Health disclaimer: This article is for informational purposes only and is not medical advice. Talk with a qualified health professional before starting supplements, changing cancer care, or making treatment decisions.